No Picture
News

FDA clears shorter treatment regimen for AbbVie’s hep C treatment, Mavyret. Will patients benefit?

Janet Hammond
AbbVie $ABBV has obtained FDA approval to administer its Mavyret hepatitis C pill as a two-month regimen, versus the 12-week course it was originally cleared for ? a move that may help expand options for the margin of covered patients who… […]

No Picture
News

EyePoint Pharmaceuticals Announces YUTIQ? Presentations at the American Academy of Ophthalmology 2019 Annual Meeting

WATERTOWN, Mass., Sept. 27, 2019 (GLOBE NEWSWIRE) — EyePoint Pharmaceuticals, Inc.?(NASDAQ: EYPT), a specialty biopharmaceutical company committed to developing and commercializing innovative ophthalmic products, today announced that two abstracts s… […]

No Picture
News

Kezar Life Sciences to Present at the 2019 Cantor Global Healthcare Conference

SOUTH SAN FRANCISCO, Calif., Sept. 27, 2019 (GLOBE NEWSWIRE) — Kezar Life Sciences, Inc.?(Nasdaq: KZR), a clinical-stage biotechnology company discovering and developing novel small molecule therapeutics to treat unmet needs in autoimmunity and canc… […]

No Picture
News

Data From Randomized Phase 2 ENTRATA Study Demonstrate Telaglenastat with Everolimus Improves Progression-Free Survival in Renal Cell Carcinoma

SOUTH SAN FRANCISCO, Calif., Sept. 28, 2019 (GLOBE NEWSWIRE) — Calithera Biosciences, Inc. (Nasdaq: CALA), a clinical stage biotechnology company focused on discovering and developing novel small molecule drugs for the treatment of cancer and other … […]